What Are the Exceptions to State Abortion Bans? May 18, 2023 News Release A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to…
Update on the Status of Medication Abortion and the Courts April 21, 2023 Blog This policy watch explains the April 21, 2023 United States Supreme Court’s ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA’s approval of mifepristone, the medication abortion pill.
Q & A: Implications of Two Conflicting Federal Court Rulings on the Availability of Medication Abortion and the FDA’s Authority to Regulate Drugs April 8, 2023 Blog This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.
Challenges to the FDA’s Approval of Medication Abortion Pills Could Curtail Access Throughout the United States March 14, 2023 News Release In anticipation of a ruling in a case with enormous implications for access to medication abortion in the United States, a new KFF brief explains the impact of this case, and others filed in federal courts, involving the FDA’s regulation of medication abortion. The case that has gotten the most…
Legal Challenges to the FDA Approval of Medication Abortion Pills March 13, 2023 Issue Brief This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA’s approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.
Medication Abortion in the Courts: What’s at Stake? March 8, 2023 News Release Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000,…
New KFF Trackers Document State and Federal Reproductive Rights Litigation Across the Country February 23, 2023 News Release KFF has created two new trackers to follow swift-moving reproductive rights litigation in the state and federal courts. The tools, which are currently tracking the status of 21 state cases in 15 states and eight federal cases, will be updated regularly as the litigation proceeds. Major cases pending in federal…
The Public, Including Women of Childbearing Age, Are Largely Confused About the Legality of Medication Abortion and Emergency Contraceptives in Their States February 1, 2023 News Release More than six months since the Supreme Court issued their Dobbs decision which overturned Roe v. Wade, there is widespread public confusion about the medication abortion pill and whether it is legal at the state level, according to the latest KFF Health Tracking Poll. The poll also finds many are…
KFF Health Tracking Poll: Early 2023 Update On Public Awareness On Abortion and Emergency Contraception February 1, 2023 Poll Finding Following the FDA approval of retail pharmacies carrying and distributing medication abortion, this poll finds that the public’s awareness and knowledge of emergency contraception and medication abortion is still lacking, especially among respondents living in states with full abortion bans.
Leading up to the 50th Anniversary of the Now-Overturned Roe, New KFF Brief Presents an Analysis of Current Legal Challenges to State Abortion Bans January 20, 2023 News Release As the nation marks the 50th anniversary of the Supreme Court of the United States landmark Roe v. Wade decision, which the Supreme Court overturned, 14 states have active litigation challenging state abortion bans and restrictions. A new KFF brief explains how individuals and organizations suing to block the bans…